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Abstract 
 
BACKGROUND: Alkaptonuria (AKU) is present from birth, yet clinical effects are considered to 
appear later in life. Morbidity of AKU, considered irrervesible, is secondary to ochronosis. Age of 
ochronosis onset is not clearly known. Nitisinone profoundly lowers homogentisic acid (HGA), the 
metabolic defect in AKU. Nitisinone also arrests ochronosis and slows progression of AKU. However, 
tyrosinaemia post-nitisinone has been associated with corneal keratopathy, rash and cognitive 
impairment in HT 1. The optimal time to start nitisinone in AKU is unknown. 
 
METHODS: In an open, cross-sectional, single site study, 32 AKU patients were to be recruited. The 
primary outcome was presence of ochronosis in an ear biopsy. Secondary outcomes included analysis 
of photographs of eyes/ears, serum/urine HGA, markers of tissue damage/inflammation/oxidation, MRI 
imaging, gait, quality of life and Alkaptonuria Severity Score Index (qAKUSSI). 
 
RESULTS: Thirty patients, with mean age (SD) 38 (14) years were recruited. Percentage pigmentation 
within ear biopsies increased with age. Ear pigmentation was detected in a 20 year old female implying 
ochronosis can start in patients before the age of 20. Gait and qAKUSSI were outside the normal range 
in all the AKU patients. 
 
CONCLUSIONS: Ochronosis can be present before age 20 years. 
 
What does this study add: It shows for the first time that features of AKU and subclinical ochronosis 
can be present from age 16 years. 
 
Impact on clinical practice: This study supports nitisinone therapy from age 16 years in AKU. An 
AKU paediatric study is needed in those younger than 16 years.  
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Key messages 
 
 Nitisinone arrests ochronosis and decreases progression of alkaptonuria 
 
 Nitisinone increases circulating tyrosine and consequences such as corneal keratopathy, 
rashes and cognitive impairment 
 
 Presence of irreversible ochronosis can justify nitisinone therapy in younger patients 
 
 AKU features established in patients as young as 16 – 20 years, suggesting that nitisinone 
therapy can be justified from age 16 years 
 
 Further studies needed to determine whether nitisinone should be administered to AKU 
patients younger than 16 years  
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Background 
Alkaptonuria (AKU) (OMIM#203500) is a rare genetic deficiency of homogentisate dioxygenase 
(HGD) (EC:1.13.11.5), characterised by high circulating homogentisic acid (HGA).[1] The frequency 
of AKU is around 1 in 250,000 to 1 in a 1,000,000 in most populations worldwide. Deposition of HGA 
in connective tissue as pigment in AKU is termed ochronosis.[2] Debilitating manifestations of AKU 
are due to ochronosis including premature arthritis, cardiac valve disease, fractures, muscle and tendon 
ruptures.[3] Despite the presence of the defect from birth, apart from dark urine, and sometimes renal 
stones, there are few osteoarticular symptoms until around age 25 years.[4]   
 
A recent study has shown that nitisinone, an inhibitor of p-hydroxyphenylpyruvate dioxygenase 
(EC:1.13.11.27) is effective in AKU.[5, 6, 7, 8] Nitisinone decreases circulating HGA, inhibits 
ochronosis in AKU mice and humans, slowing progression of human AKU, but is expensive.[9, 10] It 
is an imperfect treatment producing a different metabolic block, characterised by tyrosinaemia; toxic 
consequences, such as corneal keratopathy, eczema like skin rash and cognitive impairment can 
ensue.[11]  
 
AKU is not fully reversible and would benefit from early treatment. Mouse studies show that nitisinone 
can prevent onset of ochronosis when started soon after birth, and arrest ochronosis when started later.[9, 
10] Mouse studies revealed ochronotic pigment laid down in knee joints as early as 15 weeks.[9]  These 
findings highlight the concern that subclinical ochronosis could be damaging connective tissues early 
in life.  Starting nitisinone later in AKU is expected to result in residual disease as AKU is 
irreversible.[4] Identifying when ochronosis takes hold in AKU is important, as this information would 
allow optimal use of nitisinone, in terms of when to begin treatment. 
 
The SOFIA (Subclinical Ochronosis Features In Alkaptonuria) study was designed to identify the 
earliest age when ochronosis, microscopic and macroscopic, can be detected in patients and at what age 
it might be appropriate to begin nitisinone treatment.   
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Methods 
PATIENTS 
AKU patients, verified by elevated HGA levels, and at least 16 years old were eligible for 
inclusion. A non-AKU control group was also selected. The United Kingdom NRES granted 
ethics approval (REC NO:15/NW/0749; IRAS:180968). None of the patients in this study 
received nitisinone at the time of participation. 
 
STUDY DESIGN  
SOFIA was an open, cross-sectional, single-site (Royal Liverpool University Hospital) study, 32 AKU 
patients were to be recruited (2 males, 2 females in each age interval: 16-20, 21-25, 26-30, 31-35, 36-
40, 41-45, 46-50, over-50) covering the age spread of non-ochronotic and ochronotic groups. The 
primary outcome was the amount of ochronosis measured in ear biopsies. The secondary outcomes 
were: visible ochronosis quantification in eyes and ears; MRI examination; deviation in gait; modified 
qAKUSSI (questionnaire Alkaptonuria Severity Score Index); circulating and urine HGA; 
inflammation, cartilage damage, bone and other tissue biomarkers, and quality of life.  
 
ASSESSMENTS 
Ear cartilage: a 4mm diameter, 1-2mm thick biopsy was taken from the conchal bowl of the ear and 
stored using a standardised protocol. Ochronosis was measured by % light absorbance in microscope 
photographs (non-ochronotic tissue=0, completely ochronotic tissue=100)  (see Supplementary 
Material). 
Standardised photographs of eyes and ears were scored for ochronosis: for eyes using  qualitative and 
quantitative systems, for ears, a qualitative system (Supplementary Figure S1, Tables S1, S2).  
Modified Pfirrmann Grading System and Spondyloarthritis Research Consortium of Canada (SPARCC) 
scores of the spine and whole-organ MRI scores (WORMS) of the knee were calculated (Supplementary 
Figures S2-S5, Table S3).[12, 13, 14] Institutional MRI protocols were followed. 
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3D gait analysis was performed for 36 AKU patients (29 from SOFIA, 7 from the UK National 
Alkaptonuria Centre) and for a control group of 10 volunteers free from gait problems.[15, 16] Mean 
deviation of AKU gait from normality (MDPmean) was calculated using the MDP program 
(Supplementary Material, Figure S6).[17, 18] 
Disease questionnaires were used to calculate the modified questionnaire-based qAKUSSI  
(Supplementary Table S4).[19] 
Fasting blood samples and 24-hour urine samples were collected to measure metabolites and  biomarkers 
of inflammation, cartilage, bone and tissue.  Serum and urine HGA were quantitated by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) methods.[20, 21] Serum amyloid A (SAA) 
was analysed using a commercial assay. Quantitative determination of serum protein thiols and S-
thiolated proteins was carried out.[22] Serum protein thiols were measured by colorimetric reaction with 
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB).[23] S-thiolated proteins were measured.[24]  Protein 
Thiolation Index (PTI) was calculated as the molar ratio between total S-thiolated proteins [RSSP, where 
RS is cysteine (CySSP), cysteinylglycine (CyGlySSP), homocysteine (HcySSP), γ-glutamylcysteine 
(γGluCySSP) and glutathione (GSSP)] and the concentration of protein thiols.[25]  
The rate of connective tissue remodelling was analysed by the measurement in serum and urine of 
biomarkers of collagen and other extracellular matrix protein formation and degradation using 
competitive and sandwich ELISAs developed at Nordic Bioscience (Supplementary Table S5). The 
assays were run according to the standard procedure detailed in the references in Supplementary Table 
S5. 
 
Quality of Life was assessed using HAQ, SF-36 and KOOS questionnaires.[26, 27. 28]  
 
STATISTICAL ANALYSIS 
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Multiple linear and LOESS regression were the main analyses used. Outcome variables were plotted 
against age and regression analyses carried out. Comparisons with controls were made as appropriate. 
All analyses were conducted using SAS® version 9.3 and R version 3.3.2. 
 
Results 
Thirty AKU patients (15 male, 15 female) were recruited. Mean age: 39 years for males, 37 years for 
females, mean BMI:  25 kg/m2 for males and 23 kg/m2 for females (Supplementary Tables S6-S8). 
EAR CARTILAGE BIOPSY, EYE AND EAR PHOTOGRAPHS  
Ear biopsies from 28 samples were processed. Figure 1 shows ear and eye ochronosis measured by 
biopsy and photographs plotted against age, together with regression lines Figure 1(a) shows percentage 
of pigmentation of whole ear biopsy. Fitted regression lines were: 
% ear pigmentation =-23.5+1.43age   for males (age: p=0.001, gender: p=0.742, R2=0.39) 
% ear pigmentation =-26.9+1.43age   for females. 
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Figure 1. (a) Ochronosis score from ear biopsy plotted against age with regression lines, (b) ear 
ochronosis measured from photographs plotted against age with LOESS regression line, (c) eye 
ochronosis measured from photographs plotted against age with regression lines, (d) total quantitative 
eye pigmentation expressed as pixel value score plotted against total qualitative eye pigmentation score. 
 
Age was statistically significant (p=0.001), but not gender. The fit of this model, and some of the 
following models, was not particularly good, but it does give a strong indication of the increase in 
pigmentation with age. 
Assessment of pigment intensity by measuring light absorption of whole cartilage biopsy revealed 
pigmentation in a patient aged 20. 
Figure 1(b) shows ear ochronosis measured from photographs. Ochronosis was not detected until the 
middle of the third decade; a LOESS (Local Regression) reflects this. Figure 1(c) shows qualitative eye 
ochronosis scores. Regression lines were: 
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  Eye pigmentation =-7.3+0.36age for males  (age: p<0.001, gender: p=0.448, R2=0.50) 
  Eye pigmentation =-8.7+0.36age for females. 
Age was statistically significant, but gender not. Figure 1(d) shows the correlation of the qualitative and 
quantitative eye ochronosis scores (R2=0.83). 
 
 
MRI SCANS AND GAIT ANALYSES  
MRI spine and left knee imaging were performed on 27 and 26 AKU patients respectively. Disc 
degeneration, measured using the modified Pfirrmann score, is shown in Figure 2(a) and marrow 
oedema results, indicated by the modified SPARCC score, are shown in Figure 2(b). Knee scores are 
shown in Figure 2(c). Increases of the MRI scores with age are clearly not linear; LOESS regressions 
are shown for the two spine scores. Both show significant increases starting in the third decade of life. 
The WORMS scores generally stay low over the age range with a few exceptions.  
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Figure 2. (a) MRI Pfirrmann scores plotted against age, (b) SPARCC scores plotted against age, (c) 
WORMS scores plotted against age, (d) MDPmean plotted against age. 
 
Figure 2(d) shows the mean movement deviation profile (MDPmean) plotted against age for AKU patients 
and controls together with a linear regression line for controls and a LOESS regression for the AKU 
patients. Deviation from normal gait was found even in the younger patients, and a steep incline after 
50 years.  
MDPmean =2.44–0.01age for Controls. 
Supplementary Figures S7 and S8 show a linear clustering and a 2D visualisation of the AKU patients 
and controls.  
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MODIFIED qAKUSSI   
Figure 3(a) shows total modified qAKUSSI plotted against age;  Figures 3(b)-(d) show its components 
parts of clinical features, spine rheumatology and non-spine rheumatology. The corresponding 
regressions  are: 
  qAKUSSI   = -8.53+1.15age for males      (age: p<0.001, gender: p=0.780, R2=0.47) 
  qAKUSSI    = -10.41+1.15age for females 
  qAKUSSI_clin  = -7.31+0.67age for males      (age: p=0.001, gender: p=0.316, R2=0.36) 
  qAKUSSI_clin  = -12.35+0.67age for females. 
  qAKUSSI_spine  = -1.32+0.22age for males      (age: p=0.002, gender: p=0.076, R2=0.35) 
  qAKUSSI_spine =1.91+0.22age for females. 
  qAKUSSI_nonspine  = 0.05+0.26age for males      (age: p=0.017, gender: p=0.995, R2=0.20) 
  qAKUSSI_nonspine  = 0.03+0.26age for females. 
There were no significant differences for gender; all regressions showed a significant increase with age.  
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Figure 3. Modified qualitative alkaptonuria Severity Score Index (modified qAKUSSI): (a) total 
modified qAKUSSI, (b) qAKUSSI, clinical features, (c) aAKUSSI, spine rheumatology, (d) qAKUSSI, 
non-spine rhematology. 
 
HGA, BIOMARKERS AND  METABOLITE ANALYSES  
Figure 4 shows some results obtained for HGA measurements, the inflammation biomarker, SAA, and 
connective tissue damage markers. Figures 4(a), (b) show serum HGA and HGA clearance against age. 
The regression equations are: 
  Serum_HGA  =17.4+0.28age for males      (age: p=0.006, gender: p=0.465, R2=0.26) 
  Serum_HGA  =19.2+0.28age for females 
  HGA_clearance  =1322-11.8age for males      (age: p=0.007, gender: p=0.934, R2=0.26) 
  HGA_clearance  =1313-11.8age for females 
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Gender was not significant, but serum HGA significantly increased and HGA clearance significantly 
decreased with age. Supplementary Figure S9 shows 24-hour urine HGA plotted against age. 
 
Figures 4(c-e) show SAA, CyGlySSP and PTI plotted against age and fitted regression lines. SAA and 
PTI significantly increased with age, but with no significant difference between groups. The regression 
lines for CyGlySSP showed significantly different slopes and intercepts for groups.[19-22] 
  SAA   = 8.5+0.43age for AKU       (age: p=0.047, group: p=0.667, R2=0.07)* 
  SAA   =10.8+0.43age for Controls 
  CyGlySSP   =22.1-0.20age for AKU     (age: p<0.001, group: p=0.005, 
  CyGlySSP   =25.4+0.04age for Controls       (age*group interaction: p=0.002, R2=0.25) 
  PTI    =0.31+0.002age for AKU (age: p=0.015, group: p=0.090, R2=0.14) 
  PTI    =0.28+0.002age for Controls 
* Two outliers removed. 
Supplementary Figure S10 shows extra inflammatory and oxidative markers. 
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Figure 4. (a) Serum HGA (mol/L), (b) HGA clearance (ml/min),  (c) SAA (ng/ml), (d) CyGlySSP 
(M), (e) PTI, (f) Urine C1M_cr (ng/(mol), (g) Serum TIM (ng/ml), (h) Serum P1NP (ng/ml)  
 
Figures 4(f)-(h) show uC1M_cr, TIM and P1NP plotted against age together with regression lines. The 
regression lines for the two groups for uC1M_cr have marginally significantly different slopes and 
significantly different intercepts. TIM has significantly different slopes and intercepts for the two 
groups. P1NP significantly decreases with age for AKU patients and controls at the same rate, but with 
mean P1NP higher for AKU patients.  
  uC1M_cr  =3.59-0.05age for AKU      (age: p=0.004, group: p=0.004, 
  uC1M_cr  =1.65-0.03age for Controls     age*group interaction: p=0.056, R2=0.30) 
  TIM  =157+4.09age for AKU       (age: p=0.047, group: p=326,  
  TIM   =223+0.52age for Controls      age*group interaction: p=0.039, R2=0.30) 
  P1NP   =172-1.43age for AKU       (age: p=0.022, group: p=0.002, R2=0.22) 
  P1NP  =121-1.43age for Controls 
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Supplementary Figure S11 shows the biomarkers not covered in the main text, plotted against age for 
AKU patients and controls. 
 
QUALITY OF LIFE 
 
Figure 5 shows 6 of the 33 quality of life measurements: HAQ Disability Index, HAQ Pain score, SF36 
Physical Functioning score, SF36 General Health score, KOOS Sport and Recreation score and KOOS 
Quality of Life score. The regression equations were: 
 
  HAQ_DI   = -0.73+0.03age for males      (age: p<0.001, gender: p=0.676, R2=0.61) 
  HAQ_DI    = -0.68+0.03age for females 
  HAQ_Pain  = -0.81+0.05age for males      (age: p<0.001, gender: p=0.533, R2=0.71) 
  HAQ_Pain  = -0.65+0.05age for females. 
  SF36_PF   = 109.8-1.17age for males      (age: p<0.001, gender: p=0.390, R2=0.36) 
  SF36_PF  =  117.3 -1.17age for females. 
  SF36_GH  =  83.3-1.03age for males      (age: p=0.001, gender: p=0.775, R2=0.35) 
  SF36_GH   = 85.5 -1.03age for females. 
  KOOS_Sport_Rec  = 144.6-2.18age for males      (age: p<0.001, gender: p=0.938, R2=0.60) 
  KOOS_Sport_Rec = 145.3-2.18age for females. 
  KOOS_QoL  = 115.1-1.37age for males      (age: p<0.001, gender: p=0.815, R2=0.45) 
  KOOS_QoL   =117.0-1.37age for females. 
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Figure 5. Quality of life scores: (a) HAQ Disability Index, (b) HAQ Pain Score, (c) SF36 Physical 
Functioning score, (d) SF36 General Health score, (e) KOOS Sport and Recreation score, (f) KOOS 
Quality of Life score. 
 
All these measures show significant worsening of health with age but no difference between genders. 
The other QoL measures are reported in the Supplementary Material (Figures S12-S14). 
Discussion 
The SOFIA study objective was to identify the earliest age when ochronosis, microscopic and 
macroscopic, can be detected in AKU patients. Firstly, we review the published information in 
childhood AKU. It is important to clarify that none of the patients in this study received nitisinone at 
the time of participation. 
A natural history study in 2002 reported on 64 patients (ages 4 to 80 years), but described no clinical 
features in childhood.[29] A Slovak study, described childhood AKU 35 years ago, in 39 patients.[30] 
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Dark urine was present in all. Pigmentary changes in axillary regions appeared at 8-10 years. Dark 
brown to black staining of ear cerumen was present even in childhood. Ear cartilage pigmentation in a 
12 year old patient, and scleral pigmentation in a 13 year old patient, was reported, although no 
photographs were taken. The reported youngest age of arthropathy was 24 years. One 6-month old 
presented with a kidney stone.[31]  
We are the first to report on direct tissue studies in AKU, reasoning that it might be possible to identify 
pigmentation in tissue that could not be identified through overlying skin. Percentage pigmentation 
within ear biopsies increases with age, females lagging behind males. Difference between genders was 
not statistically different, probably due to the small sample size. Pigmentation was detected in a 20 year 
old female, so ochronosis can start in AKU patients before the age of 20. Eye ochronosis increased with 
age and was first detected at age 22 years. Externally, visible ear ochronosis was only detected after age 
34 years.  
AKU patients had 24-hour urine HGA and serum HGA values much higher than those of controls, 
showing no correlation with age, or gender. Serum HGA increased with age, but with no difference 
between genders, co-existing with worsening AKU. Conversely, HGA clearance decreased with age. 
The inflammation biomarkers, SAA and serum protein thiols, increased with age with no significant 
difference between AKU patients and controls. SAA by itself was not a discriminative marker 
between AKU and controls. Both circulating SAA (inflammation marker) and PTI (oxidative stress 
marker) increased with age with no significant difference between AKU patients and controls, 
confirming previous findings in AKU [32]. However, the highest SAA concentrations were found in 
younger subjects (CTR 29 years, SAA 132 mg/L; AKU 20 years, SAA 121 mg/L). Additionally, in 
both groups SAA was above the reference threshold of 10 mg/L in 21/30 subjects [33]. Since no 
additional data apart gender and age was made available on control subjects, we cannot rule out the 
hypothesis of underlying inflammatory conditions, however unlikely, raising SAA levels also in 
controls e.g. BMI [34]; this however again excludes a major role for SAA in AKU.  
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uC1M, a marker of collagen type I degradation measured in urine, decreased with age in AKU patients 
and P1NP, a marker of collagen type I formation measured in serum, decreased with age in both AKU 
and control groups. Bones are the main source of collagen type I in the human body, therefore the results 
suggest the rate of bone remodelling decreases with age. C1M measured in urine could reflect the 
remodelling of the renal tissue, suggesting the degradation of collagen type I in the kidney is decreased 
compatibly with an increase in fibrogenesis in the kidneys [35]. This hypothesis needs further 
investigation. TIM, a marker of MMP-mediated titin degradation describing cardiac remodelling, 
increased with age in AKU patients but not in controls, indicating increased remodelling of heart muscle 
with disease progression. At present, it is not possible to establish a precise age at which the biomarkers 
change dramatically. Further studies are needed with more patients at younger age with matched 
controls. 
Identifying ochronosis externally by examining the eyes and ears does not tell us about what is 
happening inside the body. It is possible that highly stressed tissues of the musculoskeletal system could 
be affected by ochronosis earlier but not easily accessible to assessment. Conventional imaging is not 
sensitive enough to identify internal ochronosis early as the changes are late; newer approaches such as 
Raman spectroscopy which are non-invasive may provide solutions. We were hoping to find biomarkers 
that could inform on potential changes in connective tissue in this study. The usefulness of such markers 
in limited in advanced AKU where there are other revealing features. In early AKU i.e. in young patients 
biomarkers are potentially more likely to prove valuable to monitor the disease, as well as inform when 
the disease has taken hold. Unfortunately, in the young, the musculoskeletal system is changing 
enormously due to physiological growth, as well as the gender differences in growth, maturation and 
development. In the present study the low numbers of young AKU patients did not allow a clear 
distinction between AKU and non-AKU controls, even though there was an apparent difference. The 
formation and deposition of the ochronotic pigment in the cartilaginous tissue renders the cartilage 
stiffer and would cause an increased remodelling of proteins from the connective tissue of cartilage, 
bone, and possibly other soft tissues. The examined markers of connective tissue remodelling, however, 
fail to show a direct correlation with initiation of ochronosis. TIM, a marker of titin degradation 
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reflecting a remodelling of the cardiac sarcomere, could be an indirect marker of ochronosis of the 
cardiac valve, causing impairment in the cardiac function. AKU is an ultrarare disease with a frequency 
of 1 in 250,000. This is the first study to examine a wide variety of AKU features in a cohort of sufficient 
size to provide reliable data. Bone, cartilage and tissue markers are likely to be beneficial if they can be 
validated in a larger young cohort of AKU patients matched to a normal cohort for age and gender. Plans 
for this further study are advanced and likely to begin shortly in the SOFIA-Paediatric study. 
The modified Pfirrmann spine scores on MRI analysis show AKU patients are unlikely to demonstrate 
degenerative lesions before age 30 years, however above 35 years they frequently show degenerative 
disc changes and overall worse Pfirrmann scores.[12] Marrow oedema lesion results (modified 
SPARCC scores) also appear to significantly rise from age of 30 years.[13] Degeneration of the knee 
(WORMS score) did not appear to be associated with age up to the middle of the fourth decade.[14] 
Despite the lack of change in spine and joints at ages younger than 30 years, the gait analysis was 
abnormal early on. The mean of Mean Deviation Profiles (MDP) for gait was significantly higher for 
AKU patients than for controls.[17, 18] The younger AKU patients all had high MDP values indicating 
that gait is affected at this early age.  
qAKUSSI scores increase with age, the mean increasing at a rate of 1.14 units per year. All qAKUSSI 
components (clinical, spine and non-spine) increase with age. Even at the ages between 16 and 20, 
scores well above zero have been observed. Clinically, this means that as AKU patients get older, they 
score higher on q-AKUSSI regardless of their gender, reflecting a worsening disease burden.  
Three QOL questionnaires showed pain increases and general quality of life decreases with age for AKU 
patients. For the HAQ questionnaire, deterioration starts around age 30 years, but this can be at the start 
of the second decade for some domains for some patients. For the SF36 questionnaire, physical functions 
steadily decrease with age. For the KOOS questionnaire, the functions decrease with age. Overall, the 
quality of life appears to seriously deteriorate from the third decade. 
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The overall conclusion is that this study has shown that ochronosis starts at an early age, before 
adulthood, but was unable to assess the earliest age that it may start. Further data is needed from a 
paediatric study if this start point is to be established. 
 
The difficulties of carrying out a human natural history study of AKU can be overcome to some extent 
by studying mouse AKU.[9, 10]  With biochemistry similar to human, mice with AKU also develop 
ochronosis, results suggesting that ochronosis begins a short time after weaning and progresses linearly 
over time. The use of nitisinone from early on in the life of an AKU mouse completely prevented the 
appearance of ochronosis. When nitisinone was administered after ochronosis was established, it 
arrested further progression.  
 
The reason for carrying out this AKU study is because of the availability of a HGA-lowering and a 
disease modifying therapy in the form of an enzyme inhibitor nitisinone. To consider using nitisinone 
early in life requires justification in the form of early ochronosis or early morbidity. The present study 
suggests the presence of apparently irreversible ochronosis and morbidity early in life.  
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ASSESSMENTS 
Ear Biopsy 
Each biopsy contained a disc of cartilage 4mm in diameter and 1-2 mm thick. The disc was 
bisected along the diameter and a thin slice of 0.8mm was taken from the cut face. This sample 
was examined using an Olympus SZH binocular microscope in darkfield mode at 7.5 X 
magnification. The biopsy section was photographed using a 9M pixels DCM 900 camera and 
images stored as TIFFS.  TIFFs were opened in Image J as 8-bit RGB images. An oval region of 
interest 3 mm long by 1 mm wide was selected and the mean colour intensity in the blue channel 
was quantified on 255 scale, transformed so that white=0 and black=255.  Following subtraction 
of the absorbance of non-ochronotic tissue the % absorbance was calculated (non-ochronotic 
tissue=0 and completely ochronotic tissue =100). Presence of ochronotic pigmentation was 
confirmed by histology on serial sections followed by Schmorl staining and microscopy (data not 
shown). 
Eye and Ear quantitative and qualitative assessments  
For quantitative analysis. JPEG image files were converted into 8-bit grey scale images using 
Image J. The images were calibrated for both size and colour for standardisation. Using the zoom 
function the temporal and nasal parts of the right and left eyes were analysed for conjunctival 
scleral pigmentation. Upon identification of pigmentation the free hand tool was used to draw 
around the area if a definitive boundary could be defined. The area, perimeter, standard deviation, 
mean, minimum and maximum pixel values were recorded for each region of pigmentation. If no 
definitive boundary was evident a sample within the area of pigmentation was taken for pixel 
value comparisons. The total quantitative score is the sum of the scleral and conjunctival pixel 
values in the temporal and nasal parts of the right and left eyes. The maximum pixel value for both 
the scleral and conjunctival pigmentation is 100 representing the darkest intensity, therefore the 
maximum score for each eye is 400. 
Figure S1. An example of eye ochronosis  
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Table S1 Qualitative scoring system for eye photographs. The score for a patient is 
the sum of scores over the four regions. 
 
    
 
 
Table S2 Qualitative scoring system for ear photographs.  
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Assessment of MRI scans  
 
Figure S2. Sagittal STIR image of an example of high T2 signal within the disc with 
disc height loss. 
 
Figure S3. Sagittal T1 image of an example of high T1 signal (arrows) crossing the 
L3/4 and L4/5 intervertebral discs representing interbody fusion.  
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Figure S4. Sagittal 3D volume spoiled echo sequence showing low signal foci in the 
hyaline cartilage consistent with chondrocalcinosis. 
 
Figure S5. Sagittal STIR sequence of the whole spine in three study participants. 5a 
is a 26 year old female, 5b is a 43 year old male and 5c is a 67 year old female.  
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5a: the youngest, shows no focus of marrow oedema and normal thoracic and lumbar 
intervertebral discs. 5b: 43 year old shows relatively advance disc degenerative changes with foci 
of bone marrow oedema at multiple vertebrae. 5c: with advanced endstage degeneration, there is 
interbody fusion at multiple levels but little oedema like signal return, mainly confined to the 
mobile non-fused levels (T2/3, T7/8 & T8/9). Note also the kyphotic deformity is much wore in 5c 
associated with the advanced disc degeneration. 
Table S3 Scoring system for MRI scan 
[Type here] 
 
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of the thoracic and lumbar spine: 
Modified Pfirrmann Grading System for thoracolumbar intervertebral disc degeneration 
 Each intervertebral disc space (12 thoracic, 5 lumbar) will be graded for degenerative 
changes using a modified Pfirrmann grading system which is an 8 point score on T2 
weighted images.  A total score for the T/L spine will be recorded. 
o Max score for a thoracolumbar spine =136 
 Additional observation per disc score 1 
o Presence of increase T2 signal within nucleus with disc height loss 
o Presence of increase T1 signal crossing disc (fusion) 
o Presence of insufficiency fracture 
 Max score =51 
SPARCC (Spondyloarthritis Research Consortium of Canada) grading of increase T2 signal 
abnormality on STIR for 6 of the most affected discovertebral units (DVU) 
 Maximum score per unit =18 
 Total maximum score for 6 DVUs =108 
Analysis of knee: 
WORMS score – semiquantitative multifeature scoring system 
 Cartilage signal & morphology – 8 point scale (0, 1, 2, 2.5, 3, 4, 5, 6), score 0-6 
o Max scores: 
 MFTJ =30, LFTJ =30, PFJ =24 
 Subarticular BM abnormality – score 0-3 
o Max scores 
 MFTJ =15, LFTJ =15, PFJ =12, Region S =3 
 Subarticular cysts – score 0-3 
o Max scores 
 MFTJ =15, LFTJ =15, PFJ =12, Region S =3 
 Bone attrition – score 0-3 
o Max scores 
 MFTJ =15, LFTJ =15, PFJ =12 
 Osteophytes – score 0-7 
o Max scores 
 MFTJ =35, LFTJ =35, PFJ =28 
 Ligament scores 
o Cruciates (anterior and posterior) 0/1 – intact/torn 
o Collaterals (medial and lateral) 0/1 – intact/torn 
 Combined ligment score =Cruciates+½ * collaterals 
 Menisci – score 0-6 (depending on scores for tears present in regions) 
 Synovial thickening and effusion – Score 0-3 for entire knee 
 Loose bodies – Score 0-3 for entire knee 
Maximum WORMS score for knee =335 
 
Additional factors 
 Presence of low intrachondral signal 
o Max scores 
 MFTJ =5, LFTJ =5, PFJ =4 
 
[Type here] 
 
 32 
Gait Analysis 
Data were collected using Vicon MX motion capture with nine optoelectronic cameras (T160 and 
T10) sampling at a frame rate of 100 Hz (Vicon, Oxford, UK). Fifteen reflective markers were 
placed on the lower limbs in accordance with the Helen Hayes model14 and patients were asked to 
walk barefoot at a self-selected speed along a 10m walkway (Supplementary Figure S6). Pre-
processed data from the 45 (X, Y, Z) marker coordinates were analysed using a self-organising 
map (SOM Toolbox 2.015) in MATLAB (R2017a, The MathWorks Inc., Massachusetts, US) to 
calculate the multi-dimensional deviation of AKU gait from normality. The marker coordinate 
data of patients and controls were expressed relative to a straight line fitted onto the progression of 
the centre of their pelvis followed by calculation of z-scores for each waveform to compensate for 
differences in marker offsets and amplitudes. The self-organising neural network was then used to 
calculate the mean deviation of AKU gait from normality (MDPmean)16,17 during three gait cycles 
of each patient, using the MDP freeware program16. Gait deviation for each patient was then 
calculated as the average of three walks, plotted against age 
Figure S6. Marker trajectories during gait and a stick figure of the pelvis and legs 
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Modified qAKUSSI assessment  
Table S4: Modified qAKUSSI scoring system:the overall scores are the totals over 
individual feature scores  
 
Non-spine Non-Rheumatology Clinical 
features  
Scoring 
Eye Pigments (conjunctival, scleral, temporal 
and nasal) 
0,1,2,3,4,6,8 
Ear Pigments 0,1,2,3 
Prostate and kidney Stones 4 (per episode) 
Heart valve disease 8 
Hearing impairment 4 
Fracture 8 per fracture 
Muscle/ tendon/ ligament rupture 8 per rupture 
Non-spine Rheumatology 
 
Clinical joint pain score (2 for each large joint area; 14 large joint 
areas) 
Number of joint replacements (Each joint 4-Max 10 large joints) 
Spine Rheumatology 
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Clinical Spinal pain score (4 each for cervical, thoracic, lumbar and 
sacroiliac) 
 
Table S4 summarises the clinical aspects that were assessed in the modified q-AKUSSI in SOFIA.   
Eye and ear pigmentations were scored from digital images taken by the clinical photography 
department at the Royal Liverpool University Hospital. They were independently scored by one 
assessor who was blinded to patient demographics and clinical details. For the other elements of 
the modified q-AKUSSI, case notes were reviewed. 
Biomarkers 
Serum and urine HGA were quantitated by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) methods using an Agilent 6490 Triple Quadropole mass spectrometer with Jet-
Stream electrospray ionisation coupled with an Agilent 1290 Infinity II UHPLC pump and 
autosampler. Ten microliters of sample were diluted either with 0.4μmol/L 13C6-HGA in 0.1% 
formic acid (v/v) in deionised water (acidified urine samples) or 0.2μmol/L 13C6-HGA in 0.1% 
formic acid (v/v) in deionised water (deproteinised serum samples). Separation was achieved on 
an Atlantis dC18 column (100 x 3.0mm, 3μm, Waters) maintained at 35C.  Quantitation was 
achived using a matrix-matched seven point calibration curve and two product ion transitions for 
both HGA and its internal standard 13C6-HGA.       
 
Serum amyloid A (SAA) was analysed using a commercial 96-well plate solid phase sandwich 
Enzyme Linked-Immuno-Sorbent Assay (ELISA) (Human SAA, KHA0011, Invitrogen Life 
Technologies) according to manufacturer’s instruction. Plates were read on a VersaMax 
microplate reader using Ascent software (Thermo Scientific). SAA quantification was obtained 
against a second order polynomial standard curve generated with SAA standards. All the blanks, 
standards and samples were tested in duplicate. Quantitative determination of serum protein thiols 
and S-thiolated proteins was carried out. Serum protein thiols were measured by colorimetric 
reaction with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB). S-thiolated proteins were measured.  
Protein Thiolation Index (PTI) was calculated as the molar ratio between total S-thiolated proteins 
[RSSP, where RS is cysteine (CySSP), cysteinylglycine (CyGlySSP), homocysteine (HcySSP), γ-
glutamylcysteine (γGluCySSP) and glutathione (GSSP)] and the concentration of protein thiols. 
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Table S5. Markers of connective tissue damage measured in SOFIA 
Assay Specifications Measuring Measured 
in 
Reference 
C1M MMP-generated 
fragment of type I 
collagen 
Inflammation related 
to synovial 
membrane 
remodeling 
Serum (1) 
CTX-I Cathepsin-generated 
and cross-linked 
fragment of type I 
collagen 
Bone resorption Serum (2) 
P1NP N-terminal pro-
peptide of type I 
collagen 
Bone formation Serum (3) 
C2M MMP-generated 
fragment of type II 
collagen 
Cartilage remodeling Serum (4) 
C3M MMP-generated 
fragment of type III 
collagen 
Inflammation related 
to synovial 
membrane 
remodeling 
Serum (5) 
CRPM MMP-generated 
fragment of C-
reactive protein 
Local inflammation Serum (6) 
C6M MMP-generated 
fragment of type VI 
collagen 
General fibrosis Serum (7) 
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VCANM MMP-generated 
fragment of versican 
Cardiovascular 
remodeling 
Serum (8) 
MIM MMP-generated 
fragment of 
mimecan 
Cardiovascular 
remodeling 
Serum (9) 
TIM MMP-generated 
fragment of cardiac-
specific titin 
Cardiovascular 
remodeling 
Serum (10) 
U-CTX-
II 
C-telopeptide of type 
II collagen 
Cartilage remodeling Urine (11) 
U-C3M MMP-generated 
fragment of type III 
collagen 
Renal fibrosis Urine (12) 
U-C1M MMP-generated 
fragment of type I 
collagen 
Renal fibrosis Urine n/a 
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RESULTS 
 Demographics  
A total of 30 AKU patients were recruited. Half of them were males. The mean age for all patients 
was 38.1 years ranging from 16 years to 67 years. Tables S6, S7 and S8 summarise the 
demographics of this cohort. 
Table S6. Demographics of AKU cohort in SOFIA-age 
 
Table S7. Demographics of AKU cohort in SOFIA-weight 
 
Table S8. Demographics of AKU cohort in SOFIA-BMI 
 
 
Gait Analyses  
Figure S7:A 1D self-organising neural network forced a linear clustering of AKU 
patients (red) and controls (blue). Their age is indicated by the size of circles. 
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Figure S8:A 2D scatter plot visualising the topological relationships between AKU 
patients (red)  and controls (blue) as a function of their age (circle size).  
 
 
 
 
 
 
 
 
HGA 
Figure S9. 24-hour urine HGA plotted against age 
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Figure S10. Inflammatory and oxidative markers  
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  PSH    =497.1-1.54  age for AKU      (age:p=0.008, group:p=0.103, R2 =0.16) 
  PSH    =520.7-1.54  age for Controls  
  CySSP    =133.5+0.22  age for AKU      (age:p=0.383, group:p=0.209, R2 =0.04) 
  CySSP    =125.5+0.22  age for Controls       
  HcySSP   =3.76+0.11  age for AKU      (age:p=0.121, group:p=0.792, R2 =0.04) 
  HcySSP    =4.24+0.11  age for Controls 
  GluCySSP    =0.81-0.01  age for AKU      (age:p=0.001, group:p=0.0827,  
  GluCySSP    =0.54-0.00  age for Controls     age*group interaction:p=0.008, R2 =0.19)      
  GSSP   =1.60+0.00  age for AKU      (age:p=0.907, group:p=0.395, R2 =0.01) 
  GSSP    =1.51+0.00  age for Controls       
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  RSSP    =157.8-0.22  age for AKU      (age:p=0.446, group:p=0.348 R2 =0.03) 
  RSSP   =150.8-0.22  age for Controls 
Connective tissue biomarkers 
Figure S11: Levels of the biomarkers plotted against age in AKU and control 
samples  
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  C1M    =22.01+0.11age for AKU      (ag:p=0.269, group:p=0.933, R2=0.02) 
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  C1M    =22.23+0.11age for Controls  
  C2M    =0.43+0.00age for AKU      (age:p=0.335, group:p=0.458, R2=0.03) 
  C2M    =0.39+0.00age for Controls       
  C3M    =10.61+0.01age for AKU      (age:p=0.869, group:p=0.043, R2=0.07) 
  C3M    =12.33+0.01age for Control 
  C6M    =15.74-0.01age for AKU      (age:p=0.893, group:p=0.080, R2=0.05) 
  C6M    =18.42-0.01age for Controls       
  CRPM   =9.85+0.01age for AKU      (age:p=0.684, group:p=0.008, R2=0.12) 
  CRPM    =11.70+0.01age for Controls       
  CTX_I    =1.22-0.02age for AKU      (age:p<0.001, group:p=0.527, R2=0.22) 
  CTX_I   =1.15-0.02age for Controls 
  MIM   =26.57+0.11age for AKU      (age:p=0.543, group:p=0.634, R2=0.01) 
  MIM   =28.84+0.11age for Controls       
 
  VCANM  =1.40+0.00age for AKU      (age:p=0.152, group:p=0.343, R2=0.05) 
  VCANM  =1.47+0.00age for Controls  
  uC1M   =15.57-0.09age for AKU      (age:p=0.195, group:p=0.003, R2=0.16) 
  uC1M   =10.29-0.09age for Controls 
  uC3M   =606+0.16age for AKU      (age:p=0.953, group:p<0.001, R2=0.48) 
  uC3M   =120+0.16age for Controls       
  uCTX_II  =-4.19+0.27age for AKU      (age:p<0.001, group:p=0.202,  
  uCTX_II  =1.27+0.06age for Controls      age*group interaction:p=0.034, R2=0.45)** 
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  uC3M_cr  =107-0.79age for AKU      (age:p=0.121, group:p<0.001, R2=0.35) 
  uC3M_cr  =40-0.79age for Controls 
  uCTX_II_cr  =2.19-0.02age for AKU      (age:p=0.091, group:p=0.011, R2=0.14) 
  uCTX_II_cr  =1.30-0.02age for Controls 
** For patients with age > 25 
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Quality of Life 
HAQ 
A total of thirty patients completed the HAQ questionnaire. This index considers how arthritis has 
an impact on everyday life. Total score is between 0–3.0, in 0.125 increments. Increasing scores 
indicate worse functioning (score 0=no functional impairment; score 3=complete impairment). 
These scores were correlated with age. The sub-figures in Figure S11 show a clear pattern:as AKU 
patients become older, they struggle with their Activities of Daily Living (ADLs); with the 
exception of “eating” all other domains show significant correlation with age. Sub-Figure, HAQ-
Pain, shows that as patients get older, the burden of AKU arthritis pain increases and the 
debilitating effects of the ochronosis become overt (Sub-Figure, HAQ-Disability Index).  
SF36 
A total of 29 patients completed this questionnaire. Correlations with age are shown in the sub-
figures of Figure S12. All questions are scored on a scale from 0 to 100 (highest level of 
functioning possible=100, complete loss of function=0). It is clear that as AKU patients get older, 
their energy levels and physical functions decrease. In addition, their general health deteriorates 
and they experience more pain. Nonetheless, emotionally, they remain resilient (Sub-Figure, 
SF36-Limitations due to emotional problems). 
KOOS 
Twenty seven patients completed this questionnaire. Correlations with age are shown in the sub-
figures of Figure S13. As seen with the previous two tools, there is a clear deterioration in QoL, 
across all domains, with age. This can be detected as early as 35 year of age. 
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Figure S12: HAQ 
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Figure S13: SF_36 
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Figure S14: KOOS 
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